SCILEX HOLDING CO (SCLX) Stock Price & Overview
NASDAQ:SCLX • US80880W2052
Current stock price
The current stock price of SCLX is 7 USD. Today SCLX is down by -3.31%. In the past month the price increased by 9.53%. In the past year, price increased by 55.03%.
SCLX Key Statistics
- Market Cap
- 59.43M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
SCLX Stock Performance
SCLX Stock Chart
SCLX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SCLX. When comparing the yearly performance of all stocks, SCLX turns out to be only a medium performer in the overall market: it outperformed 58.28% of all stocks.
SCLX Earnings
On April 10, 2026 SCLX reported an EPS of -2.21 and a revenue of 4.79M. The company missed EPS expectations (-360.99% surprise) and missed revenue expectations (-61.17% surprise).
SCLX Forecast & Estimates
6 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 7040% is expected in the next year compared to the current price of 7.
SCLX Groups
Sector & Classification
SCLX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCLX Ownership
SCLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.26 | 870.633B | ||
| JNJ | JOHNSON & JOHNSON | 18.1 | 544.587B | ||
| MRK | MERCK & CO. INC. | 22.41 | 278.825B | ||
| PFE | PFIZER INC | 8.85 | 152.448B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.054B | ||
| ZTS | ZOETIS INC | 16.47 | 49.42B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.686B | ||
| VTRS | VIATRIS INC | 5.85 | 16.907B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.09 | 11.216B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.535B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.281B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.098B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.42 | 4.954B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SCLX
Company Profile
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Company Info
IPO: 2021-01-11
SCILEX HOLDING CO
960 San Antonio Road
Palo Alto CALIFORNIA US
Employees: 30
Phone: 13026365401
SCILEX HOLDING CO / SCLX FAQ
Can you describe the business of SCILEX HOLDING CO?
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
What is the stock price of SCILEX HOLDING CO today?
The current stock price of SCLX is 7 USD. The price decreased by -3.31% in the last trading session.
Does SCLX stock pay dividends?
SCLX does not pay a dividend.
What is the ChartMill rating of SCILEX HOLDING CO stock?
SCLX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is SCILEX HOLDING CO worth?
SCILEX HOLDING CO (SCLX) has a market capitalization of 59.43M USD. This makes SCLX a Micro Cap stock.
Can you provide the ownership details for SCLX stock?
You can find the ownership structure of SCILEX HOLDING CO (SCLX) on the Ownership tab.
What is the outstanding short interest for SCILEX HOLDING CO?
The outstanding short interest for SCILEX HOLDING CO (SCLX) is 2.69% of its float.